Comments
Loading...

Regeneron Pharmaceuticals Analyst Ratings

REGNNASDAQ
Logo brought to you by Benzinga Data
$591.85
At close: May 28, 7:16 PM EDT
$597.10
5.250.89%
After Hours: 7:16 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$1200.00
Lowest Price Target1
$547.00
Consensus Price Target1
$920.21

Regeneron Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:REGN | Benzinga

Regeneron Pharmaceuticals Inc has a consensus price target of $920.21 based on the ratings of 29 analysts. The high is $1200 issued by TD Cowen on July 23, 2024. The low is $547 issued by B of A Securities on April 17, 2025. The 3 most-recent analyst ratings were released by RBC Capital, Citigroup, and Guggenheim on May 27, 2025, May 14, 2025, and May 1, 2025, respectively. With an average price target of $817.67 between RBC Capital, Citigroup, and Guggenheim, there's an implied 36.94% upside for Regeneron Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
1
Feb
1
Mar
12
3
1
Apr
3
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.9
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

RBC Capital
Citigroup
Guggenheim
Truist Securities
Goldman Sachs

1calculated from analyst ratings

Analyst Ratings for Regeneron Pharmaceuticals

Buy NowGet Alert
05/27/2025Buy Now57.93%RBC Capital
Brian Abrahams48%
$943 → $943ReiteratesOutperform → OutperformGet Alert
05/14/2025Buy Now17.23%Citigroup
Geoff Meacham61%
$600 → $700UpgradeNeutral → BuyGet Alert
05/01/2025Buy Now35.66%Guggenheim
Yatin Suneja52%
$940 → $810MaintainsBuyGet Alert
04/30/2025Buy Now57.43%Truist Securities
Srikripa Devarakonda43%
$975 → $940MaintainsBuyGet Alert
04/30/2025Buy Now34.65%Goldman Sachs
Salveen Richter53%
$917 → $804MaintainsBuyGet Alert
04/30/2025Buy Now57.93%RBC Capital
Brian Abrahams48%
$1051 → $943MaintainsOutperformGet Alert
04/30/2025Buy Now17.23%Wells Fargo
Mohit Bansal67%
$750 → $700MaintainsOverweightGet Alert
04/30/2025Buy Now33.98%BMO Capital
Evan David Seigerman44%
$865 → $800MaintainsOutperformGet Alert
04/30/2025Buy Now6.01%UBS
Trung Huynh64%
$768 → $633MaintainsNeutralGet Alert
04/30/2025Buy Now-1.69%Baird
Brian Skorney57%
$652 → $587MaintainsNeutralGet Alert
04/29/2025Buy Now50.73%Oppenheimer
Hartaj Singh45%
$925 → $900MaintainsOutperformGet Alert
04/25/2025Buy Now9.19%Baird
Brian Skorney57%
$759 → $652MaintainsNeutralGet Alert
04/23/2025Buy Now63.29%Truist Securities
Srikripa Devarakonda43%
$1004 → $975MaintainsBuyGet Alert
04/22/2025Buy Now42.35%Canaccord Genuity
John Newman43%
$1152 → $850MaintainsBuyGet Alert
04/22/2025Buy Now16.4%Cantor Fitzgerald
Carter Gould56%
→ $695Assumes → OverweightGet Alert
04/17/2025Buy Now-8.39%B of A Securities
Tim Anderson59%
$575 → $547MaintainsUnderperformGet Alert
04/14/2025Buy Now53.58%Goldman Sachs
Salveen Richter53%
$1019 → $917MaintainsBuyGet Alert
04/09/2025Buy Now81.04%Morgan Stanley
Matthew Harrison61%
$1150 → $1081MaintainsOverweightGet Alert
04/03/2025Buy Now54.92%Oppenheimer
Hartaj Singh45%
$950 → $925MaintainsOutperformGet Alert
03/31/2025Buy Now67.48%JP Morgan
Chris Schott59%
$1100 → $1000MaintainsOverweightGet Alert
02/05/2025Buy Now27.11%Baird
Brian Skorney57%
$940 → $759MaintainsNeutralGet Alert
02/05/2025Buy Now39.68%Leerink Partners
David Risinger72%
$762 → $834UpgradeMarket Perform → OutperformGet Alert
01/28/2025Buy Now25.61%Citigroup
Geoff Meacham61%
$795 → $750MaintainsNeutralGet Alert
01/27/2025Buy Now69.65%Piper Sandler
Christopher Raymond55%
$1195 → $1013MaintainsOverweightGet Alert
01/16/2025Buy Now23.6%UBS
Trung Huynh64%
$1130 → $738DowngradeBuy → NeutralGet Alert
01/14/2025Buy Now33.14%Citigroup
Geoff Meacham61%
$895 → $795MaintainsNeutralGet Alert
01/10/2025Buy Now59.1%Oppenheimer
Hartaj Singh45%
$1000 → $950MaintainsOutperformGet Alert
01/10/2025Buy Now50.73%Wells Fargo
Mohit Bansal67%
$1050 → $900MaintainsOverweightGet Alert
01/08/2025Buy Now68.15%Truist Securities
Srikripa Devarakonda43%
$1126 → $1004MaintainsBuyGet Alert
01/07/2025Buy Now79.2%Bernstein
William Pickering38%
$1110 → $1070MaintainsOutperformGet Alert
12/10/2024Buy Now-5.38%B of A Securities
Tim Anderson59%
→ $565Reinstates → UnderperformGet Alert
11/15/2024Buy Now92.6%Wolfe Research
Alexandria Hammond41%
→ $1150Initiates → OutperformGet Alert
11/14/2024Buy Now49.89%Citigroup
Geoff Meacham61%
→ $895Initiates → NeutralGet Alert
11/06/2024Buy Now67.48%Oppenheimer
Hartaj Singh45%
$1150 → $1000MaintainsOutperformGet Alert
11/01/2024Buy Now98.29%Morgan Stanley
Matthew Harrison61%
$1235 → $1184MaintainsOverweightGet Alert
11/01/2024Buy Now103.48%RBC Capital
Brian Abrahams48%
$1260 → $1215MaintainsOutperformGet Alert
11/01/2024Buy Now78.36%Barclays
Carter Gould56%
$1080 → $1065MaintainsOverweightGet Alert
11/01/2024Buy Now100.13%Piper Sandler
Christopher Raymond55%
$1242 → $1195MaintainsOverweightGet Alert
11/01/2024Buy Now99.3%BMO Capital
Evan David Seigerman44%
$1300 → $1190MaintainsOutperformGet Alert
11/01/2024Buy Now88.58%Truist Securities
Srikripa Devarakonda43%
$1137 → $1126MaintainsBuyGet Alert
10/25/2024Buy Now111.02%RBC Capital
Brian Abrahams48%
$1260 → $1260ReiteratesOutperform → OutperformGet Alert
10/24/2024Buy Now96.78%Evercore ISI Group
Cory Kasimov68%
$1250 → $1175MaintainsOutperformGet Alert
10/24/2024Buy Now92.6%JP Morgan
Chris Schott59%
$1200 → $1150MaintainsOverweightGet Alert
10/23/2024Buy Now69.99%Cantor Fitzgerald
Olivia Brayer52%
$1015 → $1015ReiteratesNeutral → NeutralGet Alert
10/23/2024Buy Now80.87%Barclays
Carter Gould56%
$1220 → $1080MaintainsOverweightGet Alert
10/22/2024Buy Now75.85%Wells Fargo
Mohit Bansal67%
$1200 → $1050MaintainsOverweightGet Alert
10/22/2024Buy Now111.02%RBC Capital
Brian Abrahams48%
$1260 → $1260ReiteratesOutperform → OutperformGet Alert
10/16/2024Buy Now90.42%Truist Securities
Srikripa Devarakonda43%
$1200 → $1137MaintainsBuyGet Alert
10/04/2024Buy Now111.02%RBC Capital
Brian Abrahams48%
$1252 → $1260MaintainsOutperformGet Alert
09/24/2024Buy Now109.68%RBC Capital
Brian Abrahams48%
$1282 → $1252MaintainsOutperformGet Alert
09/24/2024Buy Now117.72%BMO Capital
Evan David Seigerman44%
$1300 → $1300ReiteratesOutperform → OutperformGet Alert
09/24/2024Buy Now100.97%Truist Securities
Srikripa Devarakonda43%
$1200 → $1200ReiteratesBuy → BuyGet Alert
09/24/2024Buy Now80.37%Leerink Partners
David Risinger72%
$1175 → $1077DowngradeOutperform → Market PerformGet Alert
09/23/2024Buy Now100.97%Wells Fargo
Mohit Bansal67%
$1200 → $1200ReiteratesOverweight → OverweightGet Alert
09/17/2024Buy Now114.7%RBC Capital
Brian Abrahams48%
$1282 → $1282ReiteratesOutperform → OutperformGet Alert
09/16/2024Buy Now69.99%Cantor Fitzgerald
Olivia Brayer52%
$1015 → $1015ReiteratesNeutral → NeutralGet Alert
09/09/2024Buy Now69.99%Cantor Fitzgerald
Olivia Brayer52%
$1015 → $1015ReiteratesNeutral → NeutralGet Alert
09/09/2024Buy Now114.7%RBC Capital
Brian Abrahams48%
$1250 → $1282MaintainsOutperformGet Alert
09/05/2024Buy Now109.35%RBC Capital
Brian Abrahams48%
$1250 → $1250ReiteratesOutperform → OutperformGet Alert
08/23/2024Buy Now108.01%Piper Sandler
Christopher Raymond55%
$1166 → $1242MaintainsOverweightGet Alert
08/02/2024Buy Now100.97%JP Morgan
Chris Schott59%
$1150 → $1200MaintainsOverweightGet Alert
08/02/2024Buy Now107.67%RBC Capital
Brian Abrahams48%
$1232 → $1240MaintainsOutperformGet Alert
08/02/2024Buy Now117.72%Guggenheim
Yatin Suneja52%
$1180 → $1300MaintainsBuyGet Alert
08/02/2024Buy Now100.97%Wells Fargo
Mohit Bansal67%
$1125 → $1200MaintainsOverweightGet Alert
08/02/2024Buy Now104.32%Barclays
Carter Gould56%
$1200 → $1220MaintainsOverweightGet Alert
08/02/2024Buy Now100.97%Truist Securities
Srikripa Devarakonda43%
$1135 → $1200ReiteratesBuy → BuyGet Alert
07/23/2024Buy Now100.97%TD Cowen
Tyler Van Buren45%
$1030 → $1200MaintainsBuyGet Alert
07/22/2024Buy Now67.48%Cantor Fitzgerald
Olivia Brayer52%
$925 → $1000MaintainsNeutralGet Alert
07/19/2024Buy Now95.28%Piper Sandler
Christopher Raymond55%
$1000 → $1166MaintainsOverweightGet Alert
07/18/2024Buy Now97.62%Guggenheim
Yatin Suneja52%
$1040 → $1180MaintainsBuyGet Alert
07/11/2024Buy Now97.96%Morgan Stanley
Matthew Harrison61%
$1183 → $1182MaintainsOverweightGet Alert
07/10/2024Buy Now100.97%Barclays
Carter Gould56%
$1050 → $1200MaintainsOverweightGet Alert
06/27/2024Buy Now92.93%Canaccord Genuity
John Newman43%
$1152 → $1152MaintainsBuyGet Alert
06/25/2024Buy Now95.95%Argus Research
Jasper Hellweg68%
$1060 → $1170MaintainsBuyGet Alert
06/24/2024Buy Now105.83%RBC Capital
Brian Abrahams48%
$1229 → $1229ReiteratesOutperform → OutperformGet Alert
06/17/2024Buy Now92.6%JP Morgan
Chris Schott59%
$1050 → $1150MaintainsOverweightGet Alert
06/12/2024Buy Now105.83%RBC Capital
Brian Abrahams48%
$1200 → $1229MaintainsOutperformGet Alert
06/04/2024Buy Now100.97%RBC Capital
Brian Abrahams48%
$1185 → $1200MaintainsOutperformGet Alert
05/14/2024Buy Now92.6%Evercore ISI Group
Cory Kasimov68%
→ $1150Initiates → OutperformGet Alert
05/03/2024Buy Now54.92%Cantor Fitzgerald
Olivia Brayer52%
$925 → $925ReiteratesNeutral → NeutralGet Alert
04/24/2024Buy Now72.5%TD Cowen
Tyler Van Buren45%
$1020 → $1030MaintainsBuyGet Alert
04/17/2024Buy Now84.06%UBS
Colin Bristow38%
$1090 → $1099MaintainsBuyGet Alert
04/17/2024Buy Now54.92%Cantor Fitzgerald
Olivia Brayer52%
→ $925ReiteratesNeutral → NeutralGet Alert
04/15/2024Buy Now54.92%Cantor Fitzgerald
Louise Chen53%
$925 → $925ReiteratesNeutral → NeutralGet Alert
04/12/2024Buy Now20.58%B of A Securities
Geoff Meacham61%
$710 → $720MaintainsUnderperformGet Alert
04/09/2024Buy Now99.13%RBC Capital
Brian Abrahams48%
$1189 → $1189ReiteratesOutperform → OutperformGet Alert
04/03/2024Buy Now90.09%Truist Securities
Robyn Karnauskas54%
$1135 → $1135MaintainsBuyGet Alert
03/26/2024Buy Now90.09%Truist Securities
Robyn Karnauskas54%
$1135 → $1135MaintainsBuyGet Alert
03/13/2024Buy Now86.74%Morgan Stanley
Matthew Harrison61%
$1104 → $1115MaintainsOverweightGet Alert
03/12/2024Buy Now88.41%Bernstein
William Pickering38%
→ $1125Initiates → OutperformGet Alert
03/11/2024Buy Now88.41%Bernstein
Aaron Gal53%
→ $1125Initiates → OutperformGet Alert
02/27/2024Buy Now98.29%RBC Capital
Brian Abrahams48%
$1096 → $1184MaintainsOutperformGet Alert
02/06/2024Buy Now54.92%Cantor Fitzgerald
Olivia Brayer52%
$850 → $925MaintainsNeutralGet Alert
02/05/2024Buy Now85.9%RBC Capital
Brian Abrahams48%
$1076 → $1110MaintainsOutperformGet Alert
02/05/2024Buy Now81.21%BMO Capital
Evan David Seigerman44%
$1055 → $1082MaintainsOutperformGet Alert
01/29/2024Buy Now80.2%RBC Capital
Brian Abrahams48%
$1076 → $1076ReiteratesOutperform → OutperformGet Alert
01/23/2024Buy Now70.83%Barclays
Carter Gould56%
$935 → $1020MaintainsOverweightGet Alert
01/12/2024Buy Now80.2%RBC Capital
Brian Abrahams48%
→ $1076UpgradeSector Perform → OutperformGet Alert
01/09/2024Buy Now42.35%Cantor Fitzgerald
Olivia Brayer52%
$850 → $850ReiteratesNeutral → NeutralGet Alert
12/18/2023Buy Now75.01%Truist Securities
Robyn Karnauskas54%
→ $1045ReiteratesBuy → BuyGet Alert

FAQ

Q

What is the target price for Regeneron Pharmaceuticals (REGN) stock?

A

The latest price target for Regeneron Pharmaceuticals (NASDAQ:REGN) was reported by RBC Capital on May 27, 2025. The analyst firm set a price target for $943.00 expecting REGN to rise to within 12 months (a possible 57.93% upside). 78 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Regeneron Pharmaceuticals (REGN)?

A

The latest analyst rating for Regeneron Pharmaceuticals (NASDAQ:REGN) was provided by RBC Capital, and Regeneron Pharmaceuticals reiterated their outperform rating.

Q

When was the last upgrade for Regeneron Pharmaceuticals (REGN)?

A

The last upgrade for Regeneron Pharmaceuticals Inc happened on May 14, 2025 when Citigroup raised their price target to $700. Citigroup previously had a neutral for Regeneron Pharmaceuticals Inc.

Q

When was the last downgrade for Regeneron Pharmaceuticals (REGN)?

A

The last downgrade for Regeneron Pharmaceuticals Inc happened on January 16, 2025 when UBS changed their price target from $1130 to $738 for Regeneron Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for Regeneron Pharmaceuticals (REGN)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regeneron Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regeneron Pharmaceuticals was filed on May 27, 2025 so you should expect the next rating to be made available sometime around May 27, 2026.

Q

Is the Analyst Rating Regeneron Pharmaceuticals (REGN) correct?

A

While ratings are subjective and will change, the latest Regeneron Pharmaceuticals (REGN) rating was a reiterated with a price target of $943.00 to $943.00. The current price Regeneron Pharmaceuticals (REGN) is trading at is $597.10, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch